Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Borrow

Showing results (1-10 of 93) with videos related to

Pageof 10
Sort By:
Human Vaccines & Immunotherapeutics|December 1, 2015
Interactions of conjugate vaccines and co-administered vaccinesH Findlow, R Borrow
Methods in Molecular Medicine|February 22, 2011
PCR diagnosisM Guiver, R Borrow
Paediatric Drugs|February 26, 2016
What Would be the Best Schedule for Prevention of Meningococcal Disease in All Ages? The UK ExperienceH Findlow, R Borrow
Methods in Molecular Medicine|February 22, 2011
Serogroup B and C serum bactericidal assaysR Borrow, G M Carlone
Journal of Medical Microbiology|October 3, 2002
Impact of meningococcal C conjugate vaccine in the UKP Balmer, R Borrow, E Miller
Infection and Immunity|February 17, 2001
Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protectionR Borrow, N Andrews, D Goldblatt, et al.
Methods in Molecular Medicine|February 22, 2011
Meningococcal serologyS J Gray, R Borrow, E B Kaczmarski
Vaccine|September 1, 1995
Human antibody response to meningococcal transferrin binding proteins: evidence for vaccine potentialA R Gorringe, R Borrow, A J Fox, et al.
FEMS Immunology and Medical Microbiology|June 24, 2000
Prevalence of de-O-acetylated serogroup C meningococci before the introduction of meningococcal serogroup C conjugate vaccines in the United KingdomR Borrow, E Longworth, S J Gray, et al.
Communicable Disease and Public Health|June 30, 1998
Molecular characterisation of methicillin resistant Staphylococcus aureusJ Walker, A J Fox, R Borrow, et al.
Pageof 10

Showing results (1-10 of 93) with videos related to

Sort By:
Pageof 10
Human Vaccines & Immunotherapeutics|December 1, 2015
Interactions of conjugate vaccines and co-administered vaccinesH Findlow, R Borrow
Methods in Molecular Medicine|February 22, 2011
PCR diagnosisM Guiver, R Borrow
Paediatric Drugs|February 26, 2016
What Would be the Best Schedule for Prevention of Meningococcal Disease in All Ages? The UK ExperienceH Findlow, R Borrow
Methods in Molecular Medicine|February 22, 2011
Serogroup B and C serum bactericidal assaysR Borrow, G M Carlone
Journal of Medical Microbiology|October 3, 2002
Impact of meningococcal C conjugate vaccine in the UKP Balmer, R Borrow, E Miller
Infection and Immunity|February 17, 2001
Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protectionR Borrow, N Andrews, D Goldblatt, et al.
Methods in Molecular Medicine|February 22, 2011
Meningococcal serologyS J Gray, R Borrow, E B Kaczmarski
Vaccine|September 1, 1995
Human antibody response to meningococcal transferrin binding proteins: evidence for vaccine potentialA R Gorringe, R Borrow, A J Fox, et al.
FEMS Immunology and Medical Microbiology|June 24, 2000
Prevalence of de-O-acetylated serogroup C meningococci before the introduction of meningococcal serogroup C conjugate vaccines in the United KingdomR Borrow, E Longworth, S J Gray, et al.
Communicable Disease and Public Health|June 30, 1998
Molecular characterisation of methicillin resistant Staphylococcus aureusJ Walker, A J Fox, R Borrow, et al.
Pageof 10